BioNTech (BNTX) has concluded its Phase 2 clinical trial for colorectal cancer.

28 Aug 2026 · 13:15 UTC

Observed price moves

BNTX+2.19%15 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next. We pay about $120,000 a month for the newswires behind this feed.